Biodexa Pharmaceuticals (BDRX) announced that the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis. This marks the first European site activation for the registrational Serenta trial, representing a major milestone in expanding FAP treatment options to European patients who currently have no approved non-surgical therapeutic alternatives.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals files to sell 3.38M units
- Biodexa Pharmaceuticals’ Phase 3 Serenta Trial Approved in Europe
- Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP
- Biodexa Pharmaceuticals’ Phase 3 Trial Update: A Potential Breakthrough in FAP Treatment
- Biodexa Pharmaceuticals files $100M mixed securities shelf